Journal of Clinical Oncology, Vol 15, 76-84, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group

AJ Provisor, LJ Ettinger, JB Nachman, MD Krailo, JT Makley, EJ Yunis, AG Huvos, DL Betcher, ES Baum, CT Kisker and JS Miser
Methodist Hospital of Indiana, Indianapolis, USA.

PURPOSE: The specific aims of this study were to improve event-free survival (EFS) in patients with newly diagnosed nonmetastatic osteosarcoma of an extremity using the histologic response to neoadjuvant chemotherapy to determine postoperative chemotherapy; to evaluate a uniform histologic grading system that measures tumor response; and to identify patient characteristics that might influence EFS and survival. PATIENTS AND METHODS: Two hundred sixty-eight patients with nonmetastatic osteosarcoma of the extremity were entered between August 1983 and October 1986. Preoperative chemotherapy consisted of four courses of high-dose methotrexate (MTX) and one course of bleomycin, cyclophosphamide, and dactinomycin (BCD). Histologic response to preoperative chemotherapy was determined by morphometric analysis. Good histologic responders (< 5% residual viable tumor) were treated postoperatively with MTX, BCD, and doxorubicin (DOX); poor histologic responders were treated with BCD, DOX, and cisplatin (CDDP). RESULTS: The 8-year EFS and survival rates were 53% and 60%, respectively. Two hundred six patients had their tumors assessed for histologic response: 28% displayed a good histologic response to preoperative chemotherapy. Good histologic responders had an 8-year postoperative EFS rate of 81% and survival rate of 87%; those with a poor histologic response had an 8-year postoperative EFS rate of 46% and survival rate of 52%. A primary tumor site in the proximal humerus or proximal femur and an elevated serum alkaline phosphatase level were associated with an increased risk of an adverse event, whereas the type of surgical procedure was not. CONCLUSION: EFS and survival appear to be directly related to histologic response to neoadjuvant chemotherapy.

This article has been cited by other articles:

				H. Nishida, H. Tsuchiya, and K. Tomita Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma J Bone Joint Surg Br, September 1, 2008; 90-B(9): 1249 - 1255. [Abstract] [Full Text] [PDF]

				B. Brounais, C. Chipoy, K. Mori, C. Charrier, S. Battaglia, P. Pilet, C. D. Richards, D. Heymann, F. Redini, and F. Blanchard Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo Clin. Cancer Res., September 1, 2008; 14(17): 5400 - 5409. [Abstract] [Full Text] [PDF]

				P. Zhang, Y. Yang, P. A. Zweidler-McKay, and D. P.M. Hughes Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis Clin. Cancer Res., May 15, 2008; 14(10): 2962 - 2969. [Abstract] [Full Text] [PDF]

				C. L. Schwartz, R. Gorlick, L. Teot, M. Krailo, Z. Chen, A. Goorin, H. E. Grier, M. L. Bernstein, and P. Meyers Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2057 - 2062. [Abstract] [Full Text] [PDF]

				M. J. Hicks, J. R. Roth, C. A. Kozinetz, and L. L. Wang Clinicopathologic Features of Osteosarcoma in Patients With Rothmund-Thomson Syndrome J. Clin. Oncol., February 1, 2007; 25(4): 370 - 375. [Abstract] [Full Text] [PDF]

				M. B. McCarville, E. H. Barton, J. R. Cameron, X. Xiong, N. C. Daw, S. C. Kaste, S. Wu, J. O. Glass, and W. E. Reddick The Cause and Clinical Significance of Central Tumor Photopenia on Thallium Scintigraphy of Pediatric Osteosarcoma of the Extremity Am. J. Roentgenol., February 1, 2007; 188(2): 572 - 578. [Abstract] [Full Text] [PDF]

				I. J. Lewis, M. A. Nooij, J. Whelan, M. R. Sydes, R. Grimer, P. C. W. Hogendoorn, M. A. Memon, S. Weeden, B. M. Uscinska, M. van Glabbeke, et al. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup J Natl Cancer Inst, January 17, 2007; 99(2): 112 - 128. [Abstract] [Full Text] [PDF]

				B. Ory, F. Blanchard, S. Battaglia, F. Gouin, F. Redini, and D. Heymann Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status Mol. Pharmacol., January 1, 2007; 71(1): 333 - 343. [Abstract] [Full Text] [PDF]

				R. K. Heck Jr., T. D. Peabody, and M. A. Simon Staging of Primary Malignancies of Bone CA Cancer J Clin, November 1, 2006; 56(6): 366 - 375. [Abstract] [Full Text] [PDF]

				G. Bacci, N. Fabbri, A. Balladelli, C. Forni, E. Palmerini, and P. Picci Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients J Bone Joint Surg Br, August 1, 2006; 88-B(8): 1071 - 1075. [Abstract] [Full Text] [PDF]

				S. Ferrari, S. Smeland, M. Mercuri, F. Bertoni, A. Longhi, P. Ruggieri, T. A. Alvegard, P. Picci, R. Capanna, G. Bernini, et al. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups J. Clin. Oncol., December 1, 2005; 23(34): 8845 - 8852. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]

				T.-K. Man, M. Chintagumpala, J. Visvanathan, J. Shen, L. Perlaky, J. Hicks, M. Johnson, N. Davino, J. Murray, L. Helman, et al. Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy Cancer Res., September 15, 2005; 65(18): 8142 - 8150. [Abstract] [Full Text] [PDF]

				P. A. Meyers, C. L. Schwartz, M. Krailo, E. S. Kleinerman, D. Betcher, M. L. Bernstein, E. Conrad, W. Ferguson, M. Gebhardt, A. M. Goorin, et al. Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate J. Clin. Oncol., March 20, 2005; 23(9): 2004 - 2011. [Abstract] [Full Text] [PDF]

				R. P. Sanders, R. Drissi, C. A. Billups, N. C. Daw, M. B. Valentine, and J. S. Dome Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma J. Clin. Oncol., September 15, 2004; 22(18): 3790 - 3797. [Abstract] [Full Text] [PDF]

				N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]

				D. P. M. Hughes, D. G. Thomas, T. J. Giordano, L. H. Baker, and K. T. McDonagh Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma Cancer Res., March 15, 2004; 64(6): 2047 - 2053. [Abstract] [Full Text] [PDF]

				K. L. Zakian, A. Shukla-Dave, P. Meyers, R. Gorlick, J. Healey, H. T. Thaler, A. G. Huvos, D. M. Panicek, and J. A. Koutcher Identification of Prognostic Markers in Bone Sarcomas Using Proton-Decoupled Phosphorus Magnetic Resonance Spectroscopy Cancer Res., December 15, 2003; 63(24): 9042 - 9047. [Abstract] [Full Text] [PDF]

				G. Bacci, S. Ferrari, A. Longhi, C. Forni, P. Ruggieri, A. Briccoli, M. De Paolis, and E. Setola Preoperative Therapy Versus Immediate Surgery in Nonmetastatic Osteosarcoma J. Clin. Oncol., December 15, 2003; 21(24): 4662 - 4663. [Full Text] [PDF]

				S. A. Paluska Persistent Knee Pain in a Recreational Runner J Am Board Fam Med, September 1, 2003; 16(5): 435 - 442. [Full Text]

				G. Bacci, A. Briccoli, M. Rocca, S. Ferrari, D. Donati, A. Longhi, F. Bertoni, P. Bacchini, S. Giacomini, C. Forni, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide Ann. Onc., July 1, 2003; 14(7): 1126 - 1134. [Abstract] [Full Text] [PDF]

				B. N. Rao and C. Rodriguez-Galindo Intra-Arterial Cisplatin in Osteosarcoma: Same Question, Different Answer Ann. Surg. Oncol., June 1, 2003; 10(5): 481 - 483. [Full Text] [PDF]

				R. M. Wilkins, J. W. Cullen, L. Odom, B. A. Jamroz, P. M. Cullen, K. Fink, S. D. Peck, S. L. Stevens, C. M. Kelly, and A. B. Camozzi Superior Survival in Treatment of Primary Nonmetastatic Pediatric Osteosarcoma of the Extremity Ann. Surg. Oncol., June 1, 2003; 10(5): 498 - 507. [Abstract] [Full Text] [PDF]

				A M Wikstrom, L Hovi, L Dunkel, and U M Saarinen-Pihkala Restoration of ovarian function after chemotherapy for osteosarcoma Arch. Dis. Child., May 1, 2003; 88(5): 428 - 431. [Abstract] [Full Text] [PDF]

				S. Ferrari, A. Briccoli, M. Mercuri, F. Bertoni, P. Picci, A. Tienghi, A. B. Del Prever, F. Fagioli, A. Comandone, and G. Bacci Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival J. Clin. Oncol., February 15, 2003; 21(4): 710 - 715. [Abstract] [Full Text] [PDF]

				M. Serra, K. Scotlandi, G. Reverter-Branchat, S. Ferrari, M. C. Manara, S. Benini, M. Incaprera, F. Bertoni, M. Mercuri, A. Briccoli, et al. Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities J. Clin. Oncol., February 1, 2003; 21(3): 536 - 542. [Abstract] [Full Text] [PDF]

				L. Aung, R. Gorlick, J. H. Healey, W. Shi, H. T. Thaler, N. A. Shorter, A. G. Huvos, and P. A. Meyers Metachronous Skeletal Osteosarcoma in Patients Treated with Adjuvant and Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma J. Clin. Oncol., January 15, 2003; 21(2): 342 - 348. [Abstract] [Full Text] [PDF]

				R. Nagarajan, J. P. Neglia, D. R. Clohisy, and L. L. Robison Limb Salvage and Amputation in Survivors of Pediatric Lower-Extremity Bone Tumors: What Are the Long-Term Implications? J. Clin. Oncol., November 15, 2002; 20(22): 4493 - 4501. [Abstract] [Full Text] [PDF]

				C. P. Gibbs Jr., K. Weber, and M. T. Scarborough Malignant Bone Tumors J. Bone Joint Surg. Am., November 1, 2001; 83(11): 1728 - 1745. [Full Text] [PDF]

				G. Bacci, S. Ferrari, F. Bertoni, P. Ruggieri, P. Picci, A. Longhi, R. Casadei, N. Fabbri, C. Forni, M. Versari, et al. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report J. Clin. Oncol., December 15, 2000; 18(24): 4016 - 4027. [Abstract] [Full Text] [PDF]

				J. S. Wunder, S. B. Bull, V. Aneliunas, P. D. Lee, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, M. J. Rock, et al. MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study J. Clin. Oncol., July 14, 2000; 18(14): 2685 - 2694. [Abstract] [Full Text] [PDF]

				R. Gorlick, A. G. Huvos, G. Heller, A. Aledo, G. P. Beardsley, J. H. Healey, and P. A. Meyers Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma J. Clin. Oncol., September 1, 1999; 17(9): 2781 - 2781. [Abstract] [Full Text] [PDF]

				M.-D. Tabone, P. Terrier, H. Pacquement, M. Brunat-Mentigny, C. Schmitt, A. Babin-Boilletot, H. H. Mahmoud, and C. Kalifa Outcome of Radiation-Related Osteosarcoma After Treatment of Childhood and Adolescent Cancer: A Study of 23 Cases J. Clin. Oncol., September 1, 1999; 17(9): 2789 - 2789. [Abstract] [Full Text] [PDF]

				C. A.S. Arndt and W. M. Crist Common Musculoskeletal Tumors of Childhood and Adolescence N. Engl. J. Med., July 29, 1999; 341(5): 342 - 352. [Full Text] [PDF]

				S. S. Bielack, B. Kempf-Bielack, U. Heise, D. Schwenzer, and K. Winkler Combined Modality Treatment for Osteosarcoma Occurring as a Second Malignant Disease J. Clin. Oncol., April 1, 1999; 17(4): 1164 - 1164. [Abstract] [Full Text] [PDF]